Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0PB0D
|
|||
Former ID |
DIB000585
|
|||
Drug Name |
SRX-251
|
|||
Synonyms |
AVN-246; SRX-108; SRX-31; SRX-74; Vasopressin V1a antagonist (Raynauds disease/dysmenorrhea), Azevan Pharmaceuticals; Vasopressin V1a antagonist (psychiatric disorders/dysmenorrhea), Azevan
Click to Show/Hide
|
|||
Indication | Dysmenorrhea [ICD-11: GA34.3; ICD-9: 625.3] | Phase 1 | [1] | |
Company |
Azevan Pharmaceuticals Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C43H48F3N5O5
|
|||
Canonical SMILES |
CN(CC1=CC(=CC=C1)C(F)(F)F)C(=O)C(CC(=O)N2CCC(CC2)N3CCCCC3)N4C(C(C4=O)N5C(COC5=O)C6=CC=CC=C6)C=CC7=CC=CC=C7
|
|||
InChI |
1S/C43H48F3N5O5/c1-47(28-31-14-11-17-33(26-31)43(44,45)46)40(53)36(27-38(52)49-24-20-34(21-25-49)48-22-9-4-10-23-48)50-35(19-18-30-12-5-2-6-13-30)39(41(50)54)51-37(29-56-42(51)55)32-15-7-3-8-16-32/h2-3,5-8,11-19,26,34-37,39H,4,9-10,20-25,27-29H2,1H3/b19-18+/t35-,36-,37-,39+/m1/s1
|
|||
InChIKey |
GOQPVIZMGXUXOL-GRLAPFOSSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Antagonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Vascular smooth muscle contraction | ||||
Reactome | Vasopressin-like receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025117) | |||
REF 2 | Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006 Feb;83(2):169-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.